CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¹Úµ¿¼ö
  • ¼Ò ¼Ó: ºñ´¢±â°ú, Àü¸³¼±¼¾ÅÍ
  • Àü¹®ºÐ¾ß : Àü¸³¼±, ½ÅÀå, ¹æ±¤, °íȯ, Ç×¾ÏÄ¡·á, ±ÙÄ¡¼ö¼ú, ·Îº¿¼ö¼ú, ºê¶óÅ°
  • Á÷ À§: ±³¼ö
  • ¸Þ ÀÏ: ·Îº¿¼ö¼ú
  • Àü È­: 1577-4488
  • ÆÑ ½º: ·Îº¿¼ö¼ú
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö: https://blog.naver.com/doctor_park
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
12 (±¹¿Ü)SCI Glomus tumor of the glans penis
11 (±¹¿Ü)IM Prediction of lymph node metastasis based on p53 and nm23-H1 expression in muscle invasive grade III transitional cell carcinoma of bladder
10 (±¹¿Ü)SCI Bilateral testicular germ cell tumors
9 (±¹¿Ü)SCI ¼ºÀÎÀÇ º¹°­³» Á¤·ù°íȯ¿¡¼­ ¹ß»ýÇÑ ³»¹è¿±µ¿Á¾¾ç
8 (±¹¿Ü)SCI Percutaneous nephrostomy versus indwelling ureteral stents in patients with bilateral nongenitourinary malignant extrinsic obstruction
7 (±¹³»)SCOPUS ´ëµ¿¸Æ ÈÄ ½ÅÁ¤¸Æ
6 (±¹¿Ü)SCI Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases
5 (±¹¿Ü)SCI ÁÖÀ§ ¸²ÇÁÀý¿¡ µ¿¹ÝµÈ ½ÅÇ÷°ü±ÙÁö¹æÁ¾ 1·Ê
4 (±¹³»)SCOPUS ÁøÇàµÈ Àü¸³¼±¾Ï¿¡¼­ È£¸£¸ó ¿ä¹ý°ú ³²¼ºÈ£¸£¸ó ¼ö¿ëü ¹× p53´Ü¹éÀÇ ¹ßÇö ¾ç»ó
3 (±¹³»)±âŸ Serum tumor markers and treatment outcome in patients with intermediate-volume nonseminomatous germ cell tumors
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 19 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729